Otoimmün Hastalıklarda Probiyotikler Bir Tedavi Yöntemi Olabilir mi?

Öz

Probiyotikler, günümüzde gastrointestinal enfeksiyonlar başta olmak üzere, ürogenital ve periodontal enfeksiyonların tedavi ve profilaksisinde sıklıkla kullanılmaktadır. Gastrointestinal sistemin mikrobiyatanın en çok olduğu bölgedir. Diyet, toksinler, ilaçlar, patojenler ve çeşitli çevresel faktörler tarafından mikrobiyota değişikliğe uğrayabilir. Mikrobiyom içeriğinin değişmesi barsak bariyerinin bozulmasına ve kronik inflamatuar hastalık ve otoimmün hastalıkların gelişmesine yol açabilir. Probiyotiklerin bağışıklık mekanizmalarını da düzenlediği bilinmektedir. Konak ve mikrobiyata arasındaki ilişki hastalıkların immünopatolojik açıdan değerlendirilmesine olanak sağlamıştır. Bağışıklık dengesini korumak ve geri kazanmak için probiyotiklerin etkisi birçok çalışmanın odak noktası olmuştur. Burada mikrobiyomun otoimmün hastalıklardaki rolünü ve probiyotik kullanımının otoimmün hastalıklara etkisinden bahsedeceğiz.

Anahtar Kelimeler

• Probiyotik
• mikrobiyota
• disbiyoz
• otoimmün hastalıklar
• Lactobacillus
• Bifidobacterium

Can Probiotics be a Treatment Method in Autoimmune Diseases?

Öz

Probiotics are frequently used in the treatment and prophylaxis of gastrointestinal, urogenital, and periodontal infections. The gastrointestinal system is the region where microbiota is the most abundant. Microbiota can be altered by diet, toxins, drugs, pathogens, and various environmental factors. Changes in microbiome content can lead to disruption of the intestinal barrier and the development of chronic inflammatory and autoimmune diseases. Probiotics are also known to regulate immune mechanisms. The relationship between the host and the microbiota has enabled the evaluation of diseases from an immunopathological perspective. The effect of probiotics on maintaining and restoring the immune balance has been the focus of many studies. Here, we discuss the role of the microbiome in autoimmune diseases and the effect of probiotic use on autoimmune diseases.

Anahtar Kelimeler

• Probiotic
• microbiota
• dysbiosis
• autoimmune diseases
• Lactobacillus
• Bifidobacterium

Kaynakça

1. 1. Reinoso Webb C, Koboziev I, Furr KL, et al. Protective and Pro-Inflammatory Roles of Intestinal Bacteria. Pathophysiology. 2016;23(2):67. doi:10.1016/J.PATHOPHYS.2016.02.002
2. 2. de Oliveira GLV, Leite AZ, Higuchi BS, et al. Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology. 2017;152(1). doi:10.1111/imm.12765
3. 3. Marietta E, Mangalam AK, Taneja V, et al. Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases. Front Immunol. 2020;11. doi:10.3389/FIMMU.2020.573079
4. 4. De Luca F, Shoenfeld Y. The microbiome in autoimmune diseases. Clin Exp Immunol. 2019;195(1). doi:10.1111/cei.13158
5. 5. Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010;107(26):11971-11975. doi:10.1073/pnas.1002601107
6. 6. Ley RE, Peterson DA, Gordon JI. Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine. Cell. 2006;124(4):837-848. doi:10.1016/J.CELL.2006.02.017
7. 7. Sales-Campos H, Soares SC, Oliveira CJF. An introduction of the role of probiotics in human infections and autoimmune diseases. Crit Rev Microbiol. 2019;45(4):413-432. doi:10.1080/1040841X.2019.1621261
8. 8. Rhee K-J, Sethupathi P, Driks A, et al. Role of Commensal Bacteria in Development of Gut-Associated Lymphoid Tissues and Preimmune Antibody Repertoire. J Immunol. 2004;172(2):1118-1124. doi:10.4049/JIMMUNOL.172.2.1118

9. 9. Degruttola AK, Low D, Mizoguchi A, et al. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis. 2016;22(5):1137. doi:10.1097/MIB.0000000000000750
10. 10. Hill C, Guarner F, Reid G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014 118. 2014;11(8):506-514. doi:10.1038/nrgastro.2014.66
11. 11. Dargahi N, Johnson J, Donkor O, et al. Immunomodulatory effects of probiotics: Can they be used to treat allergies and autoimmune diseases? Maturitas. 2019;119:25-38. doi:10.1016/J.MATURITAS.2018.11.002
12. 12. Anusha RL, Umar D, Basheer B, et al. The magic of magic bugs in oral cavity: Probiotics. J Adv Pharm Technol Res. 2015;6(2):43. doi:10.4103/2231-4040.154526
13. 13. Holzapfel WH, Haberer P, Geisen R, et al. Taxonomy and important features of probiotic microorganisms in food and nutrition. Am J Clin Nutr. 2001;73(2 Suppl). doi:10.1093/AJCN/73.2.365S
14. 14. Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 2004 46. 2004;4(6):478-485. doi:10.1038/nri1373
15. 15. Belkaid Y, Hand TW. Role of the Microbiota in Immunity and inflammation. Cell. 2014;157(1):121. doi:10.1016/J.CELL.2014.03.011
16. 16. Littman DR, Rudensky AY. Th17 and Regulatory T Cells in Mediating and Restraining Inflammation. Cell. 2010;140(6):845-858. doi:10.1016/J.CELL.2010.02.021
17. 17. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A. 2010;107(27):12204-12209. doi:10.1073/PNAS.0909122107/-/DCSUPPLEMENTAL
18. 18. Fagarasan S, Kawamoto S, Kanagawa O, et al. Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis. Annu Rev Immunol. 2010;28:243-273. doi:10.1146/annurev-immunol-030409-101314
19. 19. Vangoitsenhoven R, Cresci GAM. Role of Microbiome and Antibiotics in Autoimmune Diseases. Nutr Clin Pract. 2020;35(3):406-416. doi:10.1002/NCP.10489
20. 20. Özdemir Ö. Any role for probiotics in the therapy or prevention of autoimmune diseases? Up-to-date review. J Complement Integr Med. 2013;10(1):229-250. doi:10.1515/JCIM-2012-0054/XML
21. 21. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: Past, present and future. Curr Opin Gastroenterol. 2013;29(1):79-84. doi:10.1097/MOG.0B013E32835A4B3E
22. 22. Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol Rev. 2005;204:232-249. doi:10.1111/J.0105-2896.2005.00248.X
23. 23. Roesch LF, Lorca GL, Casella G, et al. Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. ISME J. 2009;3(5):536. doi:10.1038/ISMEJ.2009.5
24. 24. Dunne JL, Triplett EW, Gevers D, et al. The intestinal microbiome in type 1 diabetes. Clin Exp Immunol. 2014;177(1):30. doi:10.1111/CEI.12321
25. 25. De Goffau MC, Luopajärvi K, Knip M, et al. Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes. 2013;62(4):1238-1244. doi:10.2337/db12-0526
26. 26. Meyers AJ, Shah RR, Gottlieb PA, et al. Altered Toll-like receptor signaling pathways in human type 1 diabetes. J Mol Med (Berl). 2010;88(12):1221-1231. doi:10.1007/S00109-010-0666-6
27. 27. Uusitalo U, Liu X, Yang J, et al. Association of Early Exposure of Probiotics and Islet Autoimmunity in the TEDDY Study. JAMA Pediatr. 2016;170(1):20. doi:10.1001/JAMAPEDIATRICS.2015.2757
28. 28. Alkanani AK, Hara N, Gottlieb PA, et al. Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes. Diabetes. 2015;64(10):3510-3520. doi:10.2337/DB14-1847
29. 29. Matsuzaki T, Nagata Y, Kado S, et al. Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. APMIS. 1997;105(8):643-649. doi:10.1111/J.1699-0463.1997.TB05066.X
30. 30. Paun A, Yau C, Danska JS. The Influence of the Microbiome on Type 1 Diabetes. J Immunol. 2017;198(2):590-595. doi:10.4049/JIMMUNOL.1601519
31. 31. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210-218. doi:10.1111/J.1750-3639.2007.00064.X
32. 32. Cosorich I, Dalla-Costa G, Sorini C, et al. High frequency of intestinal TH17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Sci Adv. 2017;3(7). doi:10.1126/SCIADV.1700492
33. 33. Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2011;108(SUPPL. 1):4615-4622. doi:10.1073/pnas.1000082107
34. 34. Berer K, Mues M, Koutrolos M, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nat 2011 4797374. 2011;479(7374):538-541. doi:10.1038/nature10554
35. 35. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139(3):485. doi:10.1016/J.CELL.2009.09.033
36. 36. Kouchaki E, Tamtaji OR, Salami M, et al. Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2017;36(5):1245-1249. doi:10.1016/J.CLNU.2016.08.015
37. 37. Ochoa-Repáraz J, Mielcarz DW, Wang Y, et al. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol. 2010;3(5):487-495. doi:10.1038/mi.2010.29
38. 38. Lavasani S, Dzhambazov B, Nouri M, et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One. 2010;5(2). doi:10.1371/journal.pone.0009009
39. 39. Kumar N, Sahoo NK, Mehan S, et al. The importance of gut-brain axis and use of probiotics as a treatment strategy for multiple sclerosis. Mult Scler Relat Disord. 2023;71(February):104547. doi:10.1016/j.msard.2023.104547
40. 40. Vaghef-Mehrabany E, Alipour B, Homayouni-Rad A, et al. Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition. 2014;30(4):430-435. doi:10.1016/J.NUT.2013.09.007
41. 41. Zamani B, Golkar HR, Farshbaf S, et al. Clinical and metabolic response to probiotic supplementation in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Int J Rheum Dis. 2016;19(9):869-879. doi:10.1111/1756-185X.12888